{"entity":{"id":"nct07130383","kind":"trial","name":"A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors","aka":[],"tldr":"A phase 2 trial of MHB036C for Injection in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, now recruiting.","summary":"A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors is a phase 2 interventional study registered as NCT07130383 by Minghui Pharmaceutical (Hangzhou) Ltd, with 210 participants planned, started 2025-09-30 and due to reach its primary completion in 2029-08. Interventions recorded: MHB036C for Injection and MHB039A for Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07130383","url":"https://clinicaltrials.gov/study/NCT07130383"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07130383","phase":"2","setting":"An Open-label Phase II Clinical Study of MHB036C for Injection Combined With MHB039A for Injection in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors","sponsor":"Minghui Pharmaceutical (Hangzhou) Ltd","enrolled":210,"outcomes":[]},"route":"/trials/nct07130383/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"mhb036c","kind":"drug","name":"MHB036C","route":"/drugs/mhb036c/"},{"id":"mhb039a","kind":"drug","name":"MHB039A","route":"/drugs/mhb039a/"}]}}